Novobiocin sodium salt ≥90%

Lieferant: ENZO LIFE SCIENCES AG

ENZOBMLA2560005EA 369 CHF
ENZOBMLA2560005 ENZOBMLA2560001
Novobiocin sodium salt ≥90%
Novobiocin sodium salt

HSP90 inhibitor


Antibiotic. Inhibitor of HSP90. Interacts with the C-terminal ATP-binding domain of HSP90 in contrast to the benzoquinone ansamycins 17-AAG (Prod. No. BML-EI308), geldanamycin (Prod. No. BML-EI280), herbimycin A (Prod. No. BML-EI227) and the chemically unrelated radicicol (Prod. No. BML-EI285), which bind to the N-terminal ATP-binding site of HSP90. Inhibitor of DNA gyrase. Useful for the production of positively supercoiled plasma DNA, targeting the nucleotide-binding site of gyrase B. Inhibits retrovirus RNA-dependent DNA polymerase. Potent inhibitor of ADP ribosylation. Inhibits LPS-induced production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, IL-6 and IL-10. Inhibits protein synthesis and alters the phosphorylation state of several cytosolic proteins. Reverses etoposide resistance in non-P-glycoprotein expressing multidrug resistant (MDR) tumor cell lines. Inducer of CD38 on cells of the myelomonocytic lineage. Forms ion channels in lipid bilayers. Inhibitor of breast cancer resistance protein (BCRP)

Formel: C₃₁H₃₅N₂NaO₁₁
MW: 634,614 g/mol
CAS-Nummer: 1476-53-5

Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Mehr About VWR